Efficacy and psychosocial impact of hepatitis C screening;Efficacite et impact psychosocial du depistage de l'hepatite C

Gastroenterologie Clinique et Biologique

Volumn 21, Issue 1 BIS, 1997, Pages

  Perez, Paul ^a  

^a UNIVERSITÉ DE BORDEAUX   (France)

Author keywords

attitude to health; hepatitis C; patient compliance; prevention and control; screening

Indexed keywords

CONFERENCE PAPER; HEALTH BEHAVIOR; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; INFECTION CONTROL; PATIENT COMPLIANCE; RISK FACTOR; SCREENING; SOCIAL ASPECT; HEALTH CARE QUALITY; MASS SCREENING; MEDICAL PSYCHOLOGY; PSYCHOLOGICAL ASPECT; REVIEW; SOCIAL PSYCHOLOGY;

HEPATITIS C; HUMANS; MASS SCREENING; PROGRAM EVALUATION; PSYCHOLOGY, MEDICAL; PSYCHOLOGY, SOCIAL;

EID: 0030934680     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Action concertée hépatite C. Réseau National de Santé Publique, 1995.
2. Cadman D, Chambers L, Feldman W, Sackett D. Assessing the effectiveness of community screening programs. JAMA 1984;251:1580-5.
3. Dab W, Salmi LR, Ancelle-Park R, Groupe de travail Epiter sur le dépistage de l'infection par le virus de l'immunodéficience humaine. Le dépistage de l'infection par le virus de l'immunodéficience humaine: évaluation des connaissances épidémiologiques. Presse Med 1993;22:1293-7.
4. Salmi LR, Mathoulin S, Perez P, Lawson-Ayayi S. Détection précoce et dépistage en santé publique et en clinique. Bordeaux: Centre national d'hémovigilance, Université Bordeaux II, 1995.
5. Cochrane A. Effectiveness and efficiency. Random reflections on health services. Cardiff: The Nuffield Provincial Hospitals Tryst, 1972.
6. Committee for Evaluating Medical Technologies in Clinical Use. Assessing medical technologies. Washington: National Academy Press, 1985.
7. Kaminski M, Blondel B. Evaluation des programmes de dépistage. Rev Epidémiol Santé Publique 1991;39:S51-63.
8. The Laboratory Centre for Disease Control. Guidelines and recommendations on the prevention and control of hepatitis C. Can J Gastroenterol 1995;9:377-86.
9. Dusheiko G, Khakoo S, Soni P, Grellier L. A rational approach to the management of hepatitis C infection. Br Med J 1996;312:357-64.
10. Pariente EA, Delvert D, Dhumeaux D. Epidémiologie de l'hépatite C en France: de la transfusion à la toxicomanie. Gastroenterol Clin Biol 1994;18:961-3.
11. Donahue JG, Munoz A, Ness PM, Brown DE, Yawn DH, McAllister HA, et al. The declining risk of post-tranfusion hepatitis C virus infection. N Engl J Med 1992;327:369-73.
12. Couroucé AM. Risque résiduel d'infections transmises par transfusion de dérivés sanguins. Rev Epidémiol Santé Publique 1994;42:463-6.
13. Lucidarme D, Foutrein P, Creusy C, Forzy G, Foutrein-Comes M, Muyssen A. Prévalence des marqueurs des hépatites C, B et D et aspects histopathologiques dans un groupe de toxicomanes intraveineux. Gastroenterol Clin Biol 1994;18:964-8.
14. Chamot E, de Saussure P, Hirschel B, Deglon J, Perrin L. Incidence of hepatitis C, hepatitis B, and HIV infections among drug users in a methadone-maintenance program. AIDS 1992;6:431-2.
15. Van den Hoek J, Van Haastrecht H, Goudsmit J, de Wolf F, Coutinho R. Prevalence, incidence and risk factors for hepatitis C virus infection among drug users in Amsterdam. J Infect Dis 1990;162:823-6.
16. Van Ameijden E, Van den Hoek J, Mientjes G, Coutinho R. A longitudinal study on the incidence and transmission patterns of HIV, HBV, and HCV infection among drug users in Amsterdam. Eur J Epidemiol 1993;9:255-62.
17. Hagan H, Des Jarlais D, Friedman S, Purchase D, Alter M. Reduced risk of hepatitis B and hepatitis C among injection drug users in the Tacoma syringe exchange program. Am J Public Health 1995;85:1531-7.
18. Carruthers S, Loxley W. Hepatitis C and young drug users: are they about to join the epidemic ? Aust J Public Health 1995;19:421-4.
19. Osmond D, Padian N, Sheppard H, Glass S, Shiboski S, Reingold A. Risk factors for hepatitis C virus positivity in heterosexual couples. JAMA 1993;269:361-5.
20. Ohto H, Terazawa S, Sasaki N, Hino K, Ishiwata C. Transmission of hepatitis C virus from mothers to infants. N Engl J Med 1994;330:744-50.
21. Dusheiko G, Roberts J. Treatment of chronic type B and C hepatitis with interferon alfa: an economic appraisal Hepatology 1995;22:1863-73.
22. Shiell A, Briggs A, Farrell G. The cost-effectiveness of alpha interferon in the treatment of chronic active hepatitis C. Med J Aust 1994;160:268-72.
23. Koff R, Seeff L. Economic modeling of treatment in chronic hepatitis B and chronic hepatitis C: promises and limitations. Hepatology 1995;22:1880-2.
24. Piccinino F, Sagnelli E, Pasquale G, Giusti G. Complications following percutaneous liver biopsy. A multicentre retrospective study on 68 276 biopsies. J Hepatol 1986;2:165-73.
25. Chuah S, Moody G, Wicks A, Mayberry J. A nationwide survey of liver biopsy. Is there a need to increase resources, manpower and training? Hepatogastroenterology 1994;41:4-8.
26. Froehlich F, Lamy O, Fried M, Gonvers J. Practice and complications of liver biopsy. Results of a nationwide survey in Switzerland. Dig Dis Sci 1993;38:1480-4.
27. Tobkes A, Nord H. Liver biopsy: review of methodology and complications. Dig Dis 1995;13:267-74.
28. Joly JP, Khouani S, Decrombecque C, Razafimahaleo A, Sevestre H, Capron JP. La ponction-biopsie hépatique échoguidée pourrait remplacer la ponction-biopsie à l'aveugle dans les hépatopathies diffuses. Une étude rétrospective chez 1293 patients. Gastroenterol Clin Biol 1995;19:703-6.
29. Minuk G, Sutherland L, Wiseman D, MacDonald F, Ding D. Prospective study of the incidence of ultrasound-detected intrahepatic and subcapsular hematomas in patients randomized to 6 or 24 hours of bed rest after percutaneous liver biopsy Gastroenterology 1987;92:290-3.
30. Haria M, Benfield P. Interferon-alpha-2a. A review of its pharmacological properties and therapeutic use in the management of viral hepatitis. Drugs 1995;50:873-96.
31. Duché A, Decocq G, Capron-Chivrac D, Andréjak M. Bilan des effets indésirables de l'interféron alpha chez 172 patients traités pour hépatite C chronique active. Thérapie 1995;50:419-23.
32. Lin R, Roach E, Zimmerman M, Strasser S, Farrell G. Interferon alfa-2b for chronic hepatitis C: effects of dose increment and duration of treatment on response rates. J Hepatol 1995;23:487-96.
33. Poynard T, Bédossa P, Chevallier M, Mathurin P, Lemonnier C, Trépo C, et al. A comparison of three interferon alfa-2b regimens for the long-term treatment of chronic non-A, non-B hepatitis. N Engl J Med 1995;332:1457-62.
34. Lunel F. Hépatite C et anomalies immunologiques. Gastroenterol Clin Biol 1994;18:829-38.
35. Marcellin P, Pouteau M, Messian O, Bok B, Erlinger S, Benhamou JP. Virus de l'hépatite C, interféron alpha et dysthyroïdie. Gastroenterol Clin Biol 1993;17:887-91.
36. Negro F, Baldi M, Mondardini A, Leandro G, Chaneac M, Manzini P. Continuous versus intermittent therapy for chronic hepatitis C with recombinant interferon alfa-2a. Gastroenterology 1994;107:479-85.
37. Lok A, Van Leeuwen D, Thomas H, Sherlock S. Psychosocial impact of chronic infection with hepatitis B virus on British patients. Genitourin Med 1985;61:279-82.
38. Ryan K, MacLennan S, Barbara J, Hewitt P. Follow up of blood donors positive for antibodies to hepatitis C virus. Br Med J 1994;308:696-7.
39. Dao T, Lecointe I, Galateau F, Freymuth F, Rideau A, Verwaerde J, el al. Apports de la biopsie hépatique et de la sérologie du virus de l'hépatite C au diagnostic d'une augmentation modérée et prolongée des aminotransférases. Gastroenterol Clin Biol 1993;17:37-43.
40. Crerar SK. Knowledge of hepatitis C amongst general practitioners in the ACT. Aust Fam Physician 1995;24:1773-5.